Institutional Shareholder Services Inc. (ISS), a leading independent proxy advisory firm, recommended on May 21, 2025, that Keros Therapeutics stockholders WITHHOLD votes from incumbent directors Dr. Mary Ann Gray and Dr. Alpna Seth. This recommendation pertains to the company's upcoming Annual Meeting of Stockholders scheduled for June 4, 2025.
ISS raised serious concerns regarding Keros' governance and concluded that greater accountability at the company is needed. ADAR1 Capital Management, Keros' largest stockholder, expressed satisfaction with the recommendation, stating it validates their concerns about the Board.
ADAR1 also highlighted that Keros intends to disclose the outcome of its strategic review process five days after the Annual Meeting. This timing means stockholders are asked to vote on critical matters without full knowledge of the Board's strategic decisions, raising additional concerns about transparency and stewardship.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.